Cell network formation.

<p>Microscopical evaluation was done in the presence of the selected treatment scenarios at 24 and 48 h post-treatment in Hs578T cell line.</p

Dual Targeted Therapy with p53 siRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell Model

<div><p>Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our <i>in vitro</i> study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT²Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.</p></div

Autophagy evaluation.

<p>Microscopical evaluation was done in the presence of the selected treatment scenarios at 24 and 48 h post-treatment in Hs578T cell line.</p

Genes that were found to be statistically significant in the experiment, classified by their fold regulation and stimulation/inhibition of genes involved in apoptosis pathway.

<p>*P-value <0.01</p><p>**P-value<0.001</p><p>***P-value<0.0001</p><p>Genes that were found to be statistically significant in the experiment, classified by their fold regulation and stimulation/inhibition of genes involved in apoptosis pathway.</p

Expression matrix of triple negative breast cancer cells after treatment with p53 siRNA, EGCG, and combined treatment.

<p>According to the bar shown below the matrix, upregulated genes are represented in red and downregulated genes are represented in green. Small black squares represent unaltered genes. Each row represents color codes for a specific gene and each column indicates the treatment strategy, which was performed in triplicate.</p